This webinar is hosted by the International Society of Pharmacometrics (ISoP) Speakers: Abstract: The development of therapeutic antagonists that target BAFF and APRIL to treat autoimmune disease is still in its…
Learn common pitfalls that pharmaceutical sponsors encounter during the regulatory eCTD submission procedure and best practices for addressing them.
Already the most sophisticated technology for physiologically based pharmacokinetic modeling (PBPK), the Simcyp Simulator has added a range of new advances in its recently release (version 23). This webinar, hosted…
Discover how Sanofi Colombia revolutionized health economics communication with BaseCase.
Transcript: The Certara community and interdisciplinary industry experts and scientists from model and form drug development bio simulation, clinical pharmacology, regulatory science, and software development come together for Certainty. Certara’s…
Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal…
Discover the latest advancements and enhancements in Phoenix version 8.5. Watch the webinar to learn more…
Rare diseases are a public health priority. FDA has launched several programs and a final guidance to address the unmet need for orphan drugs.
The acquisitions of targeted radiation therapy companies (TRT) Point Biopharma by Eli Lilly and RayzeBio by Bristol Meyer Squibb have sparked investors’ interest in this therapeutic class. A growing number…
© 2025 Certara. All Rights Reserved. | Privacy policy
